// App-Quantinova.ai

2514 : Second generation HDAC inhibitor, Quisinostat reinstates RD3 in neuroblastoma CSCs and promotes stem cell differentiation

Researchers

Presenter

  • DINESH BABU SOMASUNDARAM

Principal Investigators

  • Natarajan Aravindan

Medical Centers

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroblastoma

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 34

  • Prominin 1

Drug/Treatment

  • quisinostat

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved